Anti-VRE and anti-MRSA activities of new quinolones and their synergism with commercial antibiotics. Part 2

Yoshikazu Sakagami, Sadao Komemushi, Goro Tsukamoto, Hirosato Kondo, Akiko Yoshikawa, Osamu Muraoka

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Anti-VRE and anti-MRSA activities of new quinolone derivatives [The two quinolone derivatives are 8-[3-[(ethylamino) methyl]-1-pyrrodinyl]-7-fluoro-9,1-[(N-methylimino)methano]-5-oxo-5H- thiazolo[3,2-a]quinolone-4-carboxylic acid (compound A) and 7-fluoro-8- morpholino-9,1-[(N-methylimino) methano]-5-oxo-5H-thiazolo[3,2- a]quinolone-4-carboxylic acid (compound B)] and their synergism with commercial antibiotics were investigated. Compound A exhibited potent antibacterial activity against VRE and MRSA among the five new quinolone compounds tested, and showed superior activity to pefloxacin, ofloxacin and levofloxacin, which are clinically in use these days. With respect to the anti-VRE activity, compound A showed synergism with fosfomycin (FOM), and partial synergism with ampicillin (ABPC), gentaicin (GM), minocycline (MINO) and vancomycin hydrochloride (VCM). Partial synergism in anti-VRE activity was also observed between compound B and GM, MINO, FOM and VCM. Compound A also showed synergism with MINO and FOM in anti-MASA activity. Partial synergism was observed with ABPC, GM and VCM. Synergism with ABPC was not detected in anti-MRSA activity. On the other hand, the synergism of compound B with FOM, and the partial synergisms with ABPC, GM and MINO were also found against MRSA. No synergism with ABPC was found against MRSA. These results suggested that compound A and B could possibly reduce the daily administration dose of these antibiotics In the treatment of nosocomial infections, and also reduce the possibility of the occurrence of nosocomial infections caused by VRE and/or MRSA.

Original languageEnglish
Pages (from-to)103-109
Number of pages7
JournalBiocontrol Science
Volume13
Issue number3
Publication statusPublished - Sep 1 2008
Externally publishedYes

Fingerprint

Quinolones
Methicillin-Resistant Staphylococcus aureus
Fosfomycin
Minocycline
Anti-Bacterial Agents
Vancomycin
Cross Infection
Pefloxacin
Morpholinos
Levofloxacin
Ofloxacin
Ampicillin

All Science Journal Classification (ASJC) codes

  • Applied Microbiology and Biotechnology
  • Public Health, Environmental and Occupational Health

Cite this

Sakagami, Y., Komemushi, S., Tsukamoto, G., Kondo, H., Yoshikawa, A., & Muraoka, O. (2008). Anti-VRE and anti-MRSA activities of new quinolones and their synergism with commercial antibiotics. Part 2. Biocontrol Science, 13(3), 103-109.

Anti-VRE and anti-MRSA activities of new quinolones and their synergism with commercial antibiotics. Part 2. / Sakagami, Yoshikazu; Komemushi, Sadao; Tsukamoto, Goro; Kondo, Hirosato; Yoshikawa, Akiko; Muraoka, Osamu.

In: Biocontrol Science, Vol. 13, No. 3, 01.09.2008, p. 103-109.

Research output: Contribution to journalArticle

Sakagami, Y, Komemushi, S, Tsukamoto, G, Kondo, H, Yoshikawa, A & Muraoka, O 2008, 'Anti-VRE and anti-MRSA activities of new quinolones and their synergism with commercial antibiotics. Part 2', Biocontrol Science, vol. 13, no. 3, pp. 103-109.
Sakagami Y, Komemushi S, Tsukamoto G, Kondo H, Yoshikawa A, Muraoka O. Anti-VRE and anti-MRSA activities of new quinolones and their synergism with commercial antibiotics. Part 2. Biocontrol Science. 2008 Sep 1;13(3):103-109.
Sakagami, Yoshikazu ; Komemushi, Sadao ; Tsukamoto, Goro ; Kondo, Hirosato ; Yoshikawa, Akiko ; Muraoka, Osamu. / Anti-VRE and anti-MRSA activities of new quinolones and their synergism with commercial antibiotics. Part 2. In: Biocontrol Science. 2008 ; Vol. 13, No. 3. pp. 103-109.
@article{3eb9a95b9515476b9a82a84acb1f8366,
title = "Anti-VRE and anti-MRSA activities of new quinolones and their synergism with commercial antibiotics. Part 2",
abstract = "Anti-VRE and anti-MRSA activities of new quinolone derivatives [The two quinolone derivatives are 8-[3-[(ethylamino) methyl]-1-pyrrodinyl]-7-fluoro-9,1-[(N-methylimino)methano]-5-oxo-5H- thiazolo[3,2-a]quinolone-4-carboxylic acid (compound A) and 7-fluoro-8- morpholino-9,1-[(N-methylimino) methano]-5-oxo-5H-thiazolo[3,2- a]quinolone-4-carboxylic acid (compound B)] and their synergism with commercial antibiotics were investigated. Compound A exhibited potent antibacterial activity against VRE and MRSA among the five new quinolone compounds tested, and showed superior activity to pefloxacin, ofloxacin and levofloxacin, which are clinically in use these days. With respect to the anti-VRE activity, compound A showed synergism with fosfomycin (FOM), and partial synergism with ampicillin (ABPC), gentaicin (GM), minocycline (MINO) and vancomycin hydrochloride (VCM). Partial synergism in anti-VRE activity was also observed between compound B and GM, MINO, FOM and VCM. Compound A also showed synergism with MINO and FOM in anti-MASA activity. Partial synergism was observed with ABPC, GM and VCM. Synergism with ABPC was not detected in anti-MRSA activity. On the other hand, the synergism of compound B with FOM, and the partial synergisms with ABPC, GM and MINO were also found against MRSA. No synergism with ABPC was found against MRSA. These results suggested that compound A and B could possibly reduce the daily administration dose of these antibiotics In the treatment of nosocomial infections, and also reduce the possibility of the occurrence of nosocomial infections caused by VRE and/or MRSA.",
author = "Yoshikazu Sakagami and Sadao Komemushi and Goro Tsukamoto and Hirosato Kondo and Akiko Yoshikawa and Osamu Muraoka",
year = "2008",
month = "9",
day = "1",
language = "English",
volume = "13",
pages = "103--109",
journal = "Biocontrol Science",
issn = "1342-4815",
publisher = "Society for Antibacterial and Antifungal Agents Japan",
number = "3",

}

TY - JOUR

T1 - Anti-VRE and anti-MRSA activities of new quinolones and their synergism with commercial antibiotics. Part 2

AU - Sakagami, Yoshikazu

AU - Komemushi, Sadao

AU - Tsukamoto, Goro

AU - Kondo, Hirosato

AU - Yoshikawa, Akiko

AU - Muraoka, Osamu

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Anti-VRE and anti-MRSA activities of new quinolone derivatives [The two quinolone derivatives are 8-[3-[(ethylamino) methyl]-1-pyrrodinyl]-7-fluoro-9,1-[(N-methylimino)methano]-5-oxo-5H- thiazolo[3,2-a]quinolone-4-carboxylic acid (compound A) and 7-fluoro-8- morpholino-9,1-[(N-methylimino) methano]-5-oxo-5H-thiazolo[3,2- a]quinolone-4-carboxylic acid (compound B)] and their synergism with commercial antibiotics were investigated. Compound A exhibited potent antibacterial activity against VRE and MRSA among the five new quinolone compounds tested, and showed superior activity to pefloxacin, ofloxacin and levofloxacin, which are clinically in use these days. With respect to the anti-VRE activity, compound A showed synergism with fosfomycin (FOM), and partial synergism with ampicillin (ABPC), gentaicin (GM), minocycline (MINO) and vancomycin hydrochloride (VCM). Partial synergism in anti-VRE activity was also observed between compound B and GM, MINO, FOM and VCM. Compound A also showed synergism with MINO and FOM in anti-MASA activity. Partial synergism was observed with ABPC, GM and VCM. Synergism with ABPC was not detected in anti-MRSA activity. On the other hand, the synergism of compound B with FOM, and the partial synergisms with ABPC, GM and MINO were also found against MRSA. No synergism with ABPC was found against MRSA. These results suggested that compound A and B could possibly reduce the daily administration dose of these antibiotics In the treatment of nosocomial infections, and also reduce the possibility of the occurrence of nosocomial infections caused by VRE and/or MRSA.

AB - Anti-VRE and anti-MRSA activities of new quinolone derivatives [The two quinolone derivatives are 8-[3-[(ethylamino) methyl]-1-pyrrodinyl]-7-fluoro-9,1-[(N-methylimino)methano]-5-oxo-5H- thiazolo[3,2-a]quinolone-4-carboxylic acid (compound A) and 7-fluoro-8- morpholino-9,1-[(N-methylimino) methano]-5-oxo-5H-thiazolo[3,2- a]quinolone-4-carboxylic acid (compound B)] and their synergism with commercial antibiotics were investigated. Compound A exhibited potent antibacterial activity against VRE and MRSA among the five new quinolone compounds tested, and showed superior activity to pefloxacin, ofloxacin and levofloxacin, which are clinically in use these days. With respect to the anti-VRE activity, compound A showed synergism with fosfomycin (FOM), and partial synergism with ampicillin (ABPC), gentaicin (GM), minocycline (MINO) and vancomycin hydrochloride (VCM). Partial synergism in anti-VRE activity was also observed between compound B and GM, MINO, FOM and VCM. Compound A also showed synergism with MINO and FOM in anti-MASA activity. Partial synergism was observed with ABPC, GM and VCM. Synergism with ABPC was not detected in anti-MRSA activity. On the other hand, the synergism of compound B with FOM, and the partial synergisms with ABPC, GM and MINO were also found against MRSA. No synergism with ABPC was found against MRSA. These results suggested that compound A and B could possibly reduce the daily administration dose of these antibiotics In the treatment of nosocomial infections, and also reduce the possibility of the occurrence of nosocomial infections caused by VRE and/or MRSA.

UR - http://www.scopus.com/inward/record.url?scp=53849132758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53849132758&partnerID=8YFLogxK

M3 - Article

C2 - 18839630

AN - SCOPUS:53849132758

VL - 13

SP - 103

EP - 109

JO - Biocontrol Science

JF - Biocontrol Science

SN - 1342-4815

IS - 3

ER -